What are the characteristics of ADOCIA stock?

ADOCIA is a company operating in the Biotechnologies sector. The stock is listed on Euronext Paris under ISIN FR0011184241.

What is the recent price evolution of ADOCIA stock?

Since last close: -0.65 %. Over one week: 25.1 %. Over one year: -68.43 %.

Adocia Confirms Eligibility of Its Shares for PEA-PME

Lyon-based biotech company Adocia, specializing in diabetes and obesity treatments, confirms compliance with all eligibility criteria for the PEA-PME. Its shares can now be fully integrated into accounts benefiting from this tax advantage.

Published on Jun 11, 2026 at 10:56

ADOCIA

3.04 € -0.65 %

Add us as a preferred source on Google

Access to the PEA-PME Tax Advantage

Adocia confirms compliance with the eligibility criteria for the PEA-PME scheme set by Article L.221-32-2 of the Monetary and Financial Code. This scheme offers an income tax exemption on gains, provided that no withdrawals are made during the first five years.

Free · Every morning

Technical market signals, before the opening bell.

Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.

✓ Before 9 AM every morning ✓ Euronext data ✓ AI-powered analysis

Indicative data. No investment advice. Unsubscribe at any time.

🏢 Other stocks — Santé

🗞️ Sanofi raises its 2026 targets after a third quarter with a 14.3% increase, driven by Dupixent 🗞️ OSE Immunotherapeutics: Combi-TED meets its objective, not the Bayesian threshold 🗞️ Emeis: revenue up 6% organically over nine months, occupancy at 90.2% 🗞️ Equasens: €181.8M in revenue over nine months, organic growth at 0.9%

Context

Period

Period: 9M 2026

Key reported figures

Revenue: 0 millions d'euros
Quarterly revenue: 0 millions d'euros
Revenue growth: -97 %

Guidance from the release

« Au 30 septembre 2026, la Société disposait d'une trésorerie de 8,4 millions d'euros qui lui permettait de financer ses activités jusqu'au début du deuxième trimestre 2027 » ; « Cette opération, en prenant en compte l'utilisation complète de la convention d'avance en compte courant, ainsi que la réduction des coûts initiée par la Société depuis septembre 2026, permet d'étendre l'horizon de trésor

Risks mentioned

Dépendance critique au paiement d'étape de 20 millions de dollars conditionné à l'obtention de l'AMM de BioChaperone Lispro en Chine
Besoin de financement à court ou moyen terme et capacité à lever des fonds supplémentaires
Incertitudes des données cliniques futures et de l'évolution des marchés du diabète et de l'obésité

Opportunities identified

Paiement d'étape de 20 millions de dollars sous condition de l'approbation de BC Lispro en Chine avec redevances à deux chiffres
Accords de collaboration R&D monétisés avec les entreprises pharmaceutiques pour tester librement la technologie BioChaperone
Extension de l'horizon de trésorerie jusqu'au T1 2028 (voire 2029 si AMM obtenue) grâce à la levée de 7 millions d'euros

The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.

Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.

Access to the PEA-PME Tax Advantage

Context

Also read